These results are in line with previous studies on pancreatic cancer cells [18], in addition to ovarian cancer, where in vitro studies have shown significantly higher RBM3 levels in A2780 ovarian cancer cells compared to their cisplatin-resistant derivatives, and a decreased sensitivity to cisplatin after siRNA-mediated RBM3 suppression [16]. This evidence concerns the gene RBM3 and ovarian carcinoma.